South Korea Pompe Disease Treatment Market

South Korea Pompe Disease Treatment Market Summary:

According to Transpire Insights, a detailed research report on the market reflects that the enzyme replacement therapy application segment dominates the South Korea Pompe Disease Treatment Market, accounting for approximately 95% of the total share nationwide. Sanofi leads the market with approximately €1.31 billion in global Pompe franchise revenue and an estimated 60.4% contribution from Nexviazyme/Nexviadyme, making it the leading contributor to South Korea Pompe Disease Treatment Market development, innovation, advanced enzyme replacement therapy production, expanding treatment accessibility, and growth dynamics.

Market Snapshot

• Market Value (2025): USD 0.22 Billion.
• Expected Market Value (2026): USD 0.24 Billion.
• Estimated Market Value (2033): USD 0.35 Billion.
• Forecast CAGR (2026–2033): 5.54%.

Introduction

South Korea Pompe Disease Treatment Market is a unique subset of rare disease healthcare and biopharmaceutical market, which includes the production, distribution and use of Pompe disease therapies in South Korea. Pompe disease is a rare and inherited disorder of the lysosome in which there is a deficiency of the acid alpha-glucosidase (GAA) enzyme, leading to the deposition of glycogen within skeletal, respiratory and cardiac muscles. South Korea Pompe Disease Treatment Market is mainly dependent on enzyme replacement therapy (ERT), including recombinant enzyme therapy along with support therapy and other alternative therapies. There have been many factors contributing to the increase in patient access to Pompe disease therapies in South Korea.

Key Market Highlights: -

• By Therapy, the Enzyme Replacement Therapy (ERT) dominated the market and holds approximately 60% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• By Drug Class, the Recombinant Enzymes dominated the market and holds approximately 89.75% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• By Type, the Late-Onset Pompe Manufacturers segment dominated the market and holds approximately 84% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• South Korea increases Pompe disease access by means of rare-disease reimbursement, diagnostics support, financial support, and additional healthcare specialization facilities.

How is Technology Driving Growth in the South Korea Pompe Disease Treatment Market?

The technology is empowering the South Korea Pompe Disease Treatment Market with advanced diagnostics, next-generation enzyme replacement therapies, digital patient monitoring, and data-driven clinical management. Better testing of the activity of the GAA enzyme and genetic analysis enables doctors to make earlier and more accurate diagnoses, especially for late-onset Pompe disease. Advanced ERT formulations, such as avalglucosidase alfa, are developed to increase enzyme uptake and glycogen clearance. Digital health platforms, electronic medical records, and patient registries can improve longitudinal monitoring, coordination of care, and collaboration with specialists. At the same time, new gene therapy and precision-treatment technologies are expanding the future therapeutic landscape and driving ongoing innovation in the management of Pompe disease.

Market Drivers

The South Korea Pompe Disease Treatment Market is fuelled by the growing government initiatives for rare disease, enhanced diagnostic capabilities and greater access to specialised therapies. National rare-disease programs help patients get identified, treated and coordinated, and help the health care system. Newborn and Early Screening programs can allow for earlier diagnosis especially of infantile-onset Pompe disease. Orphan Drug Regulatory Pathways enable the development and commercialisation of novel therapies, such as next-generation enzyme replacement therapies. International pharmaceutical developers partner with Korean healthcare institutions for clinical research and therapeutic innovation. Meanwhile, Reimbursement Policies and Patient Registries help improve treatment access, disease monitoring, and long-term adoption of Pompe disease therapies across South Korea.

Restrain

High cost of lifelong ERT, reimbursement limitations & affordability issues associated with advanced therapies are expected to hinder the South Korea Pompe Disease Treatment Market. In addition, partial reversal of existing skeletal muscle damage might lead to limited long-term treatment outcomes in some patients. Concentration of specialised care on the big metropolitan hospitals can cause regional access gaps and delay of diagnosis and initiation of treatment. These factors may impact treatment adherence, healthcare expenses and the development of novel treatments for Pompe disease in South Korea.

Analysis of Prices and Consumer Behaviour

South Korea Pompe Disease Treatment Market: ERT constitutes a leading share in the South Korea Pompe Disease Treatment Market (68% of overall market; this is due to the presence of well-defined treatment regimen in the form of lifelong ERT for infantile-onset and late-onset Pompe disease). The pricing for next generation high performing ERT is anticipated to be 35% higher compared to the other therapies since these therapies feature advanced enzyme-engineered products with enhanced delivery and performance attributes. Around 45% of all treatments are related to hospital-based intravenous treatments. The volume of treatment is influenced by the presence of well-defined treatment regimen, monitoring and treatment. The segment of infantile-onset and late-onset Pompe disease accounts for approximately 70% of treatment demand due to growing diagnosis and availability of therapies. The purchasing pattern among health care providers shows that 55% prioritize treatment efficacy, safety and clinical performance while making purchasing decision. In addition, another 33% of hospitals prefer long-term procurement agreements since they try to reduce cost of treatment as well as ensure consistent availability of Pompe disease treatments in South Korea.

Who are the Key Players in the South Korea Pompe Disease Treatment Market and how do they compete?

The competitiveness in the international market for South Korea Pompe Disease Treatment Market is conditioned by companies specializing in innovations in the field of therapies, therapies dedicated to rare diseases and creation of the distribution network at a global scale. Competing not only by offering therapies but also by offering advanced therapies, innovative enzyme replacement therapies, specialized therapies and integration into clinical services and patient services, such approach to competing results in constant development of therapies, as well as in better treatment outcomes of healthcare providers.

Sanofi gains competitive advantage in the market through its innovations, such as development of advanced enzyme replacement therapies, innovative therapies for Pompe disease and patient services solutions. By developing next-generation enzyme replacement and combination therapies for Pompe disease, Amicus Therapeutics differentiates itself among its competitors. Chiesi Farmaceutici builds up its position through specialized rare-disease therapies, treatment solutions and patient healthcare approach.

Top Companies in the South Korea Pompe Disease Treatment Market

1. Sanofi
2. Amicus Therapeutics
3. Chiesi Farmaceutici
4. Takeda
5. BioMarin
6. AstraZeneca/Alexion
7. Maze Therapeutics
8. Pfizer
9. Roche
10. Novartis
11. AbbVie
12. Johnson & Johnson
13. Bayer
14. Celltrion
15. Samsung Biologics

South Korea Pompe Disease Treatment Market Segmentation 

The South Korea Pompe Disease Treatment Market share is divided into five categories:By Therapy, By Product, By Disease Type, By Route, By End User,

The Enzyme Replacement Therapy (ERT) dominated the market, accounting for nearly 60% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The South Korea Pompe Disease Treatment Market is segmented by therapy into enzyme replacement therapy, substrate reduction therapy, gene therapy, supportive therapy, respiratory therapy, physical therapy; nutritional therapy. Among these, the Enzyme Replacement Therapy (ERT) segment dominated the market, accounting for nearly 60% in 2025 and expected to increase at a significant CAGR during the forecast period. Enzyme Replacement Therapy (ERT) was the leading market segment, accounting for almost 60% in 2025, owing to established clinical uptake, reimbursement support, and sustained demand for lifelong management of Pompe disease.

The Recombinant Enzymes dominated the market, accounting for nearly 89.75% in 2025, and is expected to rise at a significant CAGR during the forecast period.

The South Korea Pompe Disease Treatment Market is segmented by product into alglucosidase alfa, avalglucosidase alfa, cipaglucosidase alfa, miglustat, gene therapy candidates, recombinant enzymes, combination therapy. Among these, the Recombinant Enzymes dominated the market, accounting for nearly 89.75% in 2025 and expected to increase at a significant CAGR during the forecast period. Recombinant enzymes were the most prevalent in 2025 due to established therapeutic efficacy, extensive clinical adoption, and their involvement in enzyme replacement therapy.

The Late-Onset Pompe dominated the market, accounting for nearly 84% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The South Korea Pompe Disease Treatment Market is segmentedby disease type into infantile-onset pompe, late-onset pompe, classic infantile, non-classic infantile, juvenile-onset, adult-onset, advanced disease. Among these, the Late-Onset Pompe dominated the market, accounting for nearly 84% in 2025 and expected to increase at a significant CAGR during the forecast period. Late-Onset Pompe was the leading disease in 2025, supported by rising diagnosis, improved disease awareness, specialist care and access to enzyme replacement therapies.

Future Market Trends for the South Korea Pompe Disease Treatment Market:-

Next-Generation ERT Adaption: The use of next-generation enzyme replacement therapies will increase, thanks to improvements in therapy efficacy and disease management, as well as changes in treatment preferences.

Earlier Diagnostics and Molecular Testing: The increased use of biochemical and molecular genetic testing will help identify Pompe patients early, allowing for treatment and special care.

Innovative Approaches to Gene Therapy: Further research in the field of AAV-based gene therapy may revolutionize Pompe disease treatment through the constant expression of the enzyme.

Recent Development

In June 2026 - Sanofi Nexviazyme Market Introduction: Sanofi reported encouraging results from its Phase 3 Baby-COMET trial for Nexviazyme, which would help in expanding treatment of Pompe disease in children and future regulatory applications.

In January 2026 – Rapid Market Access: South Korea introduced new market-access measures that would enable rapid uptakeof innovative diagnostic and therapeutic products in line with rare disease treatments.

In June 2026 - Nexviazyme Market Reimbursements: South Korea enhanced reimbursement policies for advanced enzyme replacement therapy, which would improve the availability of innovative treatment options for Pompe disease patients.

Market Segmentation

This study forecasts revenue at Japan, regional and country levels from 2020 to 2033. Transpire Insights has segmented the South Korea Pompe Disease Treatment Market based on the below-mentioned segments:

South Korea Pompe Disease Treatment Market, By Therapy

• Enzyme Replacement Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Supportive Therapy
• Respiratory Therapy
• Physical Therapy
• Nutritional Therapy

South Korea Pompe Disease Treatment Market, By Product

• Alglucosidase Alfa
• Avalglucosidase Alfa
• Cipaglucosidase Alfa
• Miglustat
• Gene Therapy Candidates
• Recombinant Enzymes
• Combination Therapy

South Korea Pompe Disease Treatment Market, By Disease Type

• Infantile-Onset Pompe
• Late-Onset Pompe
• Classic Infantile
• Non-Classic Infantile
• Juvenile-Onset
• Adult-Onset
• Advanced Disease

South Korea Pompe Disease Treatment Market, By Route

• Intravenous
• Oral
• Subcutaneous
• Intramuscular
• Intrathecal
• Gene-Delivery Route
• Other Routes

South Korea Pompe Disease Treatment Market, By End User

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Home Healthcare
• Research Institutes
• Rehabilitation Centers
• Academic Hospitals